A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections

M. L. Colombo, V. Peona, F. Ginesu, A. R. Ortu, A. Bagnato, D. Dei, F. Colombo, L. Donno

Research output: Contribution to journalArticle

Abstract

A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.

Original languageEnglish
Pages (from-to)556
Number of pages1
JournalPharmatherapeutica
Volume3
Issue number8
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections'. Together they form a unique fingerprint.

  • Cite this

    Colombo, M. L., Peona, V., Ginesu, F., Ortu, A. R., Bagnato, A., Dei, D., Colombo, F., & Donno, L. (1984). A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. Pharmatherapeutica, 3(8), 556.